MichaelRechtMDPhD
Pediatric Hematology & Oncology • New Haven, CTPediatric Coagulation Disorder Hematology, Pediatric Platelet Disorder Hematology
Professor of Clinical Pediatrics, Yale University School of Medicine, New Haven, CT
Dr. Recht is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cedar Street
New Haven, CT 06510Phone+1 203-785-4640
Summary
- Dr. Michael Recht is a pediatric hematologist/oncologist in New Haven, CT and is affiliated with Yale New Haven Hospital/Yale University School of Medicine. He received his medical degree from University of Wisconsin School of Medicine and Public Health and has been in practice 25 years. He specializes in pediatric coagulation disorder hematology and pediatric platelet disorder hematology and is experienced in platelet disorders, hemophilia, , and bleeding disorders. He has more than 100 publications and over 500 citings.
Education & Training
Yale-New Haven Medical CenterFellowship, Pediatric Hematology/Oncology, 1995 - 1998- Yale-New Haven Medical CenterResidency, Pediatrics, 1992 - 1995
University of Wisconsin School of Medicine & Public HealthClass of 1992
Certifications & Licensure
CT State Medical License 2022 - 2025
OR State Medical License 2007 - 2025- CT State Medical License 1994 - 2024
AK State Medical License 2013 - 2022
AZ State Medical License 1998 - 2009
Clinical Trials
- Evaluation of the Duration of Therapy for Thrombosis in Children Start of enrollment: 2008 Mar 01
- Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients Start of enrollment: 2009 Aug 01
- Inhibitor Development in Patients With Hemophilia A Undergoing Surgery Start of enrollment: 2011 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 867 citationsLong-term safety and efficacy of factor IX gene therapy in hemophilia BAmit C. Nathwani, Ulreke M Reiss, Edward G. D. Tuddenham, Cecilia Rosales, Pratima Chowdary
The New England Journal of Medicine. 2014-11-20 - 22 citationsBleeding symptoms and laboratory correlation in patients with severe von Willebrand disease.Ara Metjian, C. Wang, Suman L. Sood, Adam Cuker, S. M. Peterson
Haemophilia. 2009-07-10 - 86 citationsClinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia APaul Giangrande, Tatiana Andreeva, Pratima Chowdary, Silke Ehrenforth, H. Hanabusa
Thrombosis and Haemostasis. 2016-12-01
Abstracts/Posters
- One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia BMichael Recht, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Hemophilia Perspectives: Current Insights on the Evolution of Gene Therapy60th American Society of Hematology Annual Meeting - 11/30/2018
Other
- Overview of hemolytic anemias in childrenRecht M
http://www.uptodate.com/contents/overview-of-hemolytic-anemias-in-children
UpToDate, Wolters Kluwer Health - 2012-12-17
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
